Navigation Links
Significantly higher success rates with artificial insemination
Date:2/6/2008

hs there is an increased risk of miscarriages and malformations.

Choosing the 'best' ova

Which of the fertilised ova are finally implanted has usually been left up to chance. But today it is known that not all ova have the same quality. Using a special procedure the Bonn scientists can select the two most suitable candidates. 'For this we observe the ovule integument under a DIC microscope,' Dr. Montag explains. 'There it appears as a luminescent orange-red ring. The brighter this ring is and the more uniformly it shines, the greater the chance that it becomes a child.' The reason for this is that the ovule integument always seems to have a particularly uniform structure if the cell has matured under good conditions.

Normally every third ICSI is successful. But if medics used two 'good ' ova in their experiment, this rate increased to more than 50 per cent. With a 'good' and a 'bad' ovum the success rate was still around 40 per cent, using two 'bad' ones only 20 per cent. 'Mind you, two good ova are rare,' Markus Montag emphasises. 'Only with two out of ten cells does the ovule integument have an intense regular orange colour.'

Under natural conditions insemination takes place in the oviduct. After that the ovum begins to divide, while contractions of the oviduct transport it to the uterus. This process takes just under 2-3 days. When the embryo lodges in the endometrium on the sixth day after insemination, the embryo consists of several hundred cells. During the whole process the embryo is protected by the ovule integument.

The Bonn team led by Dr. Markus Montag and Professor Hans van der Ven has developed software in conjunction with the Octax Microscience Company, which analyses the image from the microscope objectively and proposes the most suitable cells. 'This way the procedure can be implemented in clinical routine without problems and without much effort,' he says.


'/>"/>

Contact: Markus Montag
Markus.Montag@ukb.uni-bonn.de
49-022-828-715-449
University of Bonn
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New findings show Enbrel significantly reduced levels of C-reactive protein
2. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
3. Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
4. Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers
5. Tonsillectomy significantly improves quality of life in adult and pediatric patients
6. Adult ADHD significantly impacts on social, financial and personal aspects of life
7. Transports Phase 2 Data Show Single Treatment SoloVir(TM) ETS Significantly Stops Progression of Cold Sore Episode
8. PET imaging significantly enhances standard imaging in lung cancer staging
9. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
10. Ranexa(R) Significantly Reduces Ischemia in Women in MERLIN TIMI-36 Study
11. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... -- Klafter & Olsen LLP has filed a,class action l..." or the,"Company") (Nasdaq: ARTC ) and certain o...Western District of Texas on behalf of all persons...Care from January 24, 2008,through July 18, 2008 (...,persons or entities who purchased call options or...
(Date:7/25/2008)...etroviral therapy may be due to genetic factors ,...new study challenges the long-held belief that the...,s ability to restore itself after HIV patients ar...y (HAART). , From 50 percent to 90 percent of H... Intravenous drug use is the main cause of both ty...
(Date:7/25/2008)...BeaconEquity.com announces the,availability of Tra... can view all of the daily trading notes for free ... Trade Alerts include: DUSA Pharmaceuticals Inc. (...(Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Ado...q: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., Joi...
(Date:7/25/2008)...ificant Improvements in Members, Health, ATLANTA,... in health,care quality management solutions for h...entered into a long-term agreement with Wellmark, ...on on Quality(SM) Incent and,Reward Best Practices...primary care clinicians to promote improved qualit...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...sociated with cancers, fibrosis and other diseases...say // exposure to asbestos may lay the groundwork... arthritis and multiple sclerosis. Researchers exa... known to be polluted by asbestos. They found thes...
... a frightening experience for children as they oft...ew study shows hypnosis could help reduce distress...re. The study included children who were schedule...y. During a VCUG, a tube is inserted into the blad...
...the poorer quality of life they will have, say res...children participated in the study . Researchers m...rt survey completed by a parent and child self-rep...otional, social and academic functioning of the ch...
...ween fast food consumption and weight gain and ins...eases the risk of obesity and type 2 diabetes. Res...rted fast food habits and changes in bodyweight an...ears. The diets of more than 3,000 young adults we...
Other Medicine News:
(Date:7/22/2008)...ility and Efficacy of Treating Patients with ...NCISCO, and YONGIN-SI, South Korea, July 22 /PRNew...tawa, Ontario), and its South,Korean partner Green...from,a Phase I clinical trial of its first-in-clas...t was well-tolerated and resulted in clear,anti-ca...
(Date:7/22/2008)...tress the Importance to Patients of Passing a ... RICHMOND, Va., July 22 /-...ow-on biologics and biopharmaceuticals, today,anno...ill present at a,Congressional briefing on Friday,...or establishing an approval pathway for follow-on,...
(Date:7/22/2008)... by Columbia University Medical Center Based on ...hnology, The Test Differentiates Squamous From N...lassifying Squamous-Cell Carcinoma of the Lung Wit... of 90 Percent,This is the First CLIA Approved Tes...as Biomarkers for Accurate Diagnosis of Lung Cance...
(Date:7/22/2008)...idual,s Genetic Risk Based on Clinical Data, Pr...al Materials, WALTHAM, Mass., July 22 /PRNewswire...ILI ), today announced the launch of an enhanced t...company,s Heart Health Genetic Test.,The test is c...Heart Health,Genetic Test by Quixtar/Amway. The ne...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1New technology illuminates protein interactions in living cells 1167 1New technology illuminates protein interactions in living cells 1167 2
...ion Therapeutics,announced today that data on two ...prednate) and ST-602 (fenretinide), will be,presen...for,Research in Vision and Ophthalmology (ARVO) in...tions, the company will be hosting a,reception for...ntly being evaluated in two phase,III clinical tri...
...erlying Cause of,Genetic Disorders and Restores Pr...2007 /PRNewswire/ -- New,preclinical data publishe...ure show that PTC124, an investigational new drug,...ious in a,preclinical model of Duchenne muscular d... 13 percent of the cases of DMD are due,to nonsens...
Other Medicine Technology:Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 2Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 3Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 4
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available.
Medicine Products: